TL118 / Teligene - LARVOL DELTA

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Teligene US | Trial completion date: Apr 2026 ➔ Apr 2027 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Solid Tumor • NTRK1 • NTRK2 • NTRK3

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Teligene US | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Apr 2026 | Initiation date: May 2024 ➔ Mar 2023 | Trial primary completion date: Dec 2025 ➔ Aug 2025

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Solid Tumor • NTRK1 • NTRK2 • NTRK3

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Teligene US | Initiation date: Jan 2024 ➔ May 2024

Trial initiation date • Oncology • Solid Tumor • NTRK1 • NTRK2 • NTRK3

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Teligene US

New P2 trial • Oncology • Solid Tumor • NTRK1 • NTRK2 • NTRK3